Cobra Biologics has successfully produced and supplied two further DNA plasmids for the production of CombiGene AB’s gene therapy drug candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy. This completes delivery of all plasmids required to progress to the next phase of the project. The production of CG01, is dependent on manufactured and specifically modified plasmids. All three plasmids delivered by Cobra are key components of the gene therapy vector ...